4.6 Article

Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Neurosciences

A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR

Christopher G. Schwarz et al.

JOURNAL OF ALZHEIMERS DISEASE (2019)

Article Clinical Neurology

ABBY A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease

Jeffrey L. Cummings et al.

NEUROLOGY (2018)

Article Medicine, General & Internal

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease

Michael F. Egan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Article Clinical Neurology

A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease

Susanne Ostrowitzki et al.

ALZHEIMERS RESEARCH & THERAPY (2017)

Article Clinical Neurology

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

Eric R. Siemers et al.

ALZHEIMERS & DEMENTIA (2016)

Review Medicine, Research & Experimental

The amyloid hypothesis of Alzheimer's disease at 25years

Dennis J. Selkoe et al.

EMBO MOLECULAR MEDICINE (2016)

Article Multidisciplinary Sciences

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease

Jeff Sevigny et al.

NATURE (2016)

Article Clinical Neurology

The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET

William E. Klunk et al.

ALZHEIMERS & DEMENTIA (2015)

Article Neurosciences

Partial volume correction in quantitative amyloid imaging

Yi Su et al.

NEUROIMAGE (2015)

Article Radiology, Nuclear Medicine & Medical Imaging

Longitudinal Amyloid Imaging Using 11C-PiB: Methodologic Considerations

Bart N. M. van Berckel et al.

JOURNAL OF NUCLEAR MEDICINE (2013)

Article Clinical Neurology

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab

Susanne Ostrowitzki et al.

ARCHIVES OF NEUROLOGY (2012)

Review Clinical Neurology

New and emerging treatments for Alzheimer's disease

Anne Corbett et al.

EXPERT REVIEW OF NEUROTHERAPEUTICS (2012)

Meeting Abstract Radiology, Nuclear Medicine & Medical Imaging

Translational studies with [11C] MK-3168, a PET tracer for fatty acid amide hydrolase (FAAH)

Aniket Joshi et al.

JOURNAL OF NUCLEAR MEDICINE (2012)

Review Neurosciences

The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes

Iryna Benilova et al.

NATURE NEUROSCIENCE (2012)

Article Medicine, General & Internal

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

Randall J. Bateman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Review Neurosciences

Soluble forms of tau are toxic in Alzheimer's disease

Katherine J. Kopeikina et al.

TRANSLATIONAL NEUROSCIENCE (2012)

Article Radiology, Nuclear Medicine & Medical Imaging

Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects

Abhinay D. Joshi et al.

JOURNAL OF NUCLEAR MEDICINE (2012)

Article Radiology, Nuclear Medicine & Medical Imaging

The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease

Benjamin A. Thomas et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)

Article Medicine, General & Internal

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

Christopher M. Clark et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)

Review Neurosciences

Amyloid Clearance as a Treatment Target Against Alzheimer's Disease

Alexander Kurz et al.

JOURNAL OF ALZHEIMERS DISEASE (2011)

Review Medicine, General & Internal

Current Treatment and Recent Clinical Research in Alzheimer's Disease

Judith Neugroschl et al.

MOUNT SINAI JOURNAL OF MEDICINE (2010)

Review Cell Biology

Soluble protein oligomers in neurodegeneration:: lessons from the Alzheimer's amyloid β-peptide

Christian Haass et al.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)